Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 17/20 | 0.63 |
| ▸ | KDR | P35968 | 13/20 | 0.63 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | STK10 | O94804 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | CDK11B | P21127 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861349 | 0.91 | BRAF (0.63) | BRAFKDRKITFLT1PDGFRB | |
| SCHEMBL2853166 | 0.91 | BRAF (0.62) | BRAFKDRKITFLT1STK10 | |
| SCHEMBL2855483 | 0.91 | BRAF (0.65) | BRAFKDRKITFLT1STK10 | |
| SCHEMBL2860386 | 0.91 | BRAF (0.64) | BRAFKDRKITFLT1STK10 | |
| SCHEMBL2857396 | 0.90 | BRAF (0.52) | BRAFKDRCYP2C9RAF1 | |
| SCHEMBL2853217 | 0.89 | BRAF (0.49) | BRAFKDRCYP2C9RAF1 | |
| SCHEMBL2853808 | 0.88 | KDR (0.74) | BRAFKDRKITFLT1PDGFRB | |
| SCHEMBL2857364 | 0.87 | BRAF (0.47) | BRAFKDRCYP2C9 | |
| SCHEMBL2856107 | 0.86 | BRAF (0.47) | BRAFKDRKITFLT1STK10 | |
| SCHEMBL13185006 | 0.84 | BRAF (0.56) | BRAFKDRKITFLT1STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3201100-A2 | DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAME | Monosol, LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-3137540-A1 | STABILIZING COMPOSITIONS FOR STABILIZING MATERIALS AGAINST ULTRAVIOLET LIGHT AND THERMAL DEGRADATION | Cytec Industries Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015168389-A1 | STABILIZING COMPOSITIONS FOR STABILIZING MATERIALS AGAINST ULTRAVIOLET LIGHT AND THERMAL DEGRADATION | CYTEC INDUSTRIES INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2183316-A2 | TREE RESISTANT INSULATION COMPOSITIONS | General Cable Technologies Corporation (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009021050-A2 | TREE RESISTANT INSULATION COMPOSITIONS | GENERAL CABLE TECHNOLOGIES, CORP. (US) | 2009-02-12 | — | — | WO | disclosed |
| EP-1089987-A1 | BENZOCYCLE-SUBSTITUTED TRIAZINE AND PYRIMIDINE ULTRAVIOLET LIGHT ABSORBERS | CYTEC TECHNOLOGY CORP. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1089985-A1 | RED-SHIFTED TRISARYL-1,3,5-TRIAZINE ULTRAVIOLET LIGHT ABSORBERS | CYTEC TECHNOLOGY CORP. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067225-A1 | BENZOCYCLE-SUBSTITUTED TRIAZINE AND PYRIMIDINE ULTRAVIOLET LIGHT ABSORBERS | CYTEC TECHNOLOGY CORP. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067224-A1 | RED-SHIFTED TRISARYL-1,3,5-TRIAZINE ULTRAVIOLET LIGHT ABSORBERS | CYTEC TECHNOLOGY CORP. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885KDR 983/4885KIT 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.